Showing results (81-90 of 170) with videos related to

Sort By:
Pageof 17
The Canadian Journal of Urology|March 7, 2017
Improving prostate cancer care collaboratively - a multidisciplinary, formal, consensus-based approachAndrew Loblaw, Jack Barkin, Roger Buckley, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|July 18, 2020
Role of urinary cations in the etiology of interstitial cystitis: A multisite studyC Lowell Parsons, Sulabha Argade, Robert J Evans, et al.
BJU International|February 22, 2011
Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trialClaus G Roehrborn, Jack Barkin, Paul Siami, et al.
Hormone Molecular Biology and Clinical Investigation|May 12, 2015
Testosterone and risk of breast cancer: appraisal of existing evidenceAbdulmaged M Traish, Katharina Fetten, Martin Miner, et al.
Contemporary Clinical Trials|September 1, 2007
Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study designPaul Siami, Claus G Roehrborn, Jack Barkin, et al.
Clinical Therapeutics|September 1, 2004
A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinenceJack Barkin, Jacques Corcos, Sidney Radomski, et al.
The Canadian Journal of Urology|December 15, 2011
Results of high intensity focused ultrasound treatment of prostate cancer: early Canadian experience at a single centerDean S Elterman, Jack Barkin, Sidney B Radomski, et al.
European Urology|November 18, 2008
The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT studyClaus G Roehrborn, Paul Siami, Jack Barkin, et al.
International Journal of Clinical Practice|June 10, 2022
Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR TrialDavid Staskin, Jeffrey Frankel, Susann Varano, et al.
European Urology|October 15, 2009
The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT studyClaus G Roehrborn, Paul Siami, Jack Barkin, et al.
Pageof 17